A Phase I/II Trial of Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas.

Trial Profile

A Phase I/II Trial of Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 29 Jul 2016

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Vorinostat (Primary)
  • Indications Lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jun 2016 Status changed from recruiting to discontinued as per sponsor's request.
    • 07 Dec 2008 Planned initiation date changed from 1 Nov 2008 to 1 Jan 2009 as reported by ClinicalTrials.gov.
    • 21 Nov 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top